Recombinant Burkholderia sp. UPF0060 membrane protein Bcep18194_A4425 (Bcep18194_A4425)

What is Recombinant Burkholderia sp. UPF0060 membrane protein Bcep18194_A4425?

Recombinant Full Length Burkholderia sp. UPF0060 membrane protein Bcep18194_A4425 (UniProt ID: Q39HP5) is a 110-amino acid protein derived from Burkholderia lata. It is expressed in E. coli with an N-terminal His tag to facilitate purification processes. The protein is generally supplied as a lyophilized powder with greater than 90% purity as determined by SDS-PAGE analysis. This membrane protein belongs to the UPF0060 family, which consists of proteins with currently uncharacterized functions, making it a subject of interest for researchers investigating novel membrane protein functions .

What are the optimal storage and handling conditions for Bcep18194_A4425?

To maintain the structural integrity and functionality of Bcep18194_A4425, the following storage and handling protocols are recommended:

For optimal results, the lyophilized protein should be briefly centrifuged prior to opening to ensure all material is at the bottom of the vial. For reconstitution, sterile deionized water should be used to achieve a concentration of 0.1-1.0 mg/mL. Addition of glycerol to a final concentration of 5-50% is recommended for long-term storage, with 50% being the default recommendation .

How can Bcep18194_A4425 be utilized in drug development studies?

Recombinant full-length proteins like Bcep18194_A4425 serve as valuable tools in drug development pipelines. For utilizing this protein in drug discovery:

• Target Validation Studies: The protein can be immobilized on sensor chips for surface plasmon resonance (SPR) analysis to screen potential binding partners and inhibitors.

• High-Throughput Screening: Develop fluorescence-based or colorimetric assays where Bcep18194_A4425 activity is measured in the presence of compound libraries.

• Structure-Based Drug Design: If crystal structures are available, computer-aided drug design can identify potential binding pockets within Bcep18194_A4425.

• Binding Affinity Measurements: Isothermal titration calorimetry (ITC) or microscale thermophoresis (MST) can quantify binding parameters between the protein and candidate compounds.

This approach mirrors successful strategies used for other membrane proteins in drug discovery programs. By understanding the binding mechanism of drug candidates to Bcep18194_A4425, researchers can evaluate activity, specificity, and potential off-target effects .

What experimental designs are recommended for studying protein-protein interactions involving Bcep18194_A4425?

When investigating protein-protein interactions involving Bcep18194_A4425, several complementary approaches can be employed:

For membrane proteins like Bcep18194_A4425, special considerations include using appropriate detergents for solubilization without disrupting native interactions. Similar methodologies have been successfully employed in studies examining protein-protein interactions in other systems, such as the demonstrated physical interactions between TSHR and CD40 proteins .

What statistical approaches are most appropriate for analyzing experimental data with Bcep18194_A4425?

The statistical analysis of experimental data involving Bcep18194_A4425 should be carefully designed based on the specific experimental setup:

• For binding studies: Nonlinear regression analysis to determine KD values and binding kinetics, with consideration of one-site vs. two-site binding models.

• For functional assays: Dose-response curves analyzed using appropriate statistical software to determine EC50/IC50 values.

• For comparative studies:

  • Student's t-test for comparing two experimental conditions

  • ANOVA for multiple comparisons, followed by post-hoc tests (e.g., Tukey's HSD)

  • Non-parametric alternatives (Mann-Whitney, Kruskal-Wallis) when normality assumptions are violated

• For reproducibility assessment: Calculate coefficient of variation (CV) across technical and biological replicates.

When designing experiments, power analysis should be conducted to determine appropriate sample sizes that minimize both Type I (false positive) and Type II (false negative) errors. Effect size calculations are crucial for interpreting the biological significance of observed differences beyond statistical significance .

What reconstitution protocols optimize Bcep18194_A4425 functionality for in vitro studies?

The reconstitution of lyophilized Bcep18194_A4425 requires careful attention to maintain protein functionality:

• Initial Reconstitution:

  • Centrifuge vial briefly before opening

  • Reconstitute in deionized sterile water to 0.1-1.0 mg/mL

  • Gentle mixing without vortexing to avoid protein denaturation

• Buffer Optimization:

  • For functional studies: Consider including 5-10% glycerol to stabilize the protein

  • For membrane insertion studies: Gradual dilution into buffers containing appropriate detergents (DDM, CHAPS, or Brij-35)

• Proteoliposome Preparation:

  • Mix purified Bcep18194_A4425 with synthetic lipids in detergent

  • Remove detergent using Bio-Beads or dialysis

  • Verify incorporation using sucrose density gradient centrifugation

• Activity Verification:

  • For transport studies: Monitor substrate movement across membranes using fluorescent probes

  • For binding studies: Confirm proper folding using circular dichroism spectroscopy

The recommended storage buffer (Tris/PBS-based buffer with 6% trehalose at pH 8.0) provides an initial stabilizing environment, but buffer optimization may be required for specific experimental applications .

How can post-translational modifications of Bcep18194_A4425 be studied?

Investigating post-translational modifications (PTMs) of Bcep18194_A4425 requires specialized techniques:

• Mass Spectrometry Approaches:

  • Liquid chromatography-tandem mass spectrometry (LC-MS/MS) following tryptic digestion

  • Top-down proteomics for intact protein analysis

  • Targeted multiple reaction monitoring (MRM) for quantification of specific modifications

• Site-Directed Mutagenesis:

  • Systematic mutation of potential modification sites

  • Functional comparison between wild-type and mutant proteins

• Modification-Specific Antibodies:

  • Western blotting using antibodies against common PTMs (phosphorylation, glycosylation)

  • Immunoprecipitation coupled with mass spectrometry

• Biochemical Assays:

  • Phosphatase treatment to confirm phosphorylation

  • Glycosidase digestion to analyze glycan structures

For bacterial membrane proteins like Bcep18194_A4425, common PTMs include phosphorylation, lipidation, and glycosylation. Each modification potentially influences protein localization, stability, and function, making their characterization essential for comprehensive understanding of protein behavior .

What are the methodological approaches for determining the three-dimensional structure of Bcep18194_A4425?

Determining the three-dimensional structure of membrane proteins like Bcep18194_A4425 presents unique challenges requiring specialized techniques:

For Bcep18194_A4425 specifically, its relatively small size (110 amino acids) makes it potentially amenable to solution NMR after isotopic labeling. Detergent micelles, nanodiscs, or lipidic cubic phases can be employed to mimic the membrane environment while maintaining protein stability during structural studies .

How can researchers investigate the functional role of Bcep18194_A4425 in bacterial physiology?

To elucidate the physiological function of Bcep18194_A4425:

• Gene Knockout/Knockdown Studies:

  • CRISPR-Cas9 genome editing in Burkholderia lata

  • RNA interference or antisense approaches

  • Phenotypic characterization of mutant strains (growth rates, stress responses)

• Protein Localization:

  • Fluorescent protein fusion constructs

  • Immunogold electron microscopy with specific antibodies

  • Subcellular fractionation followed by Western blotting

• Transcriptomic/Proteomic Profiling:

  • RNA-Seq comparison between wild-type and knockout strains

  • Quantitative proteomics to identify affected pathways

  • Metabolomic analysis to detect changes in cellular metabolism

• Interactome Mapping:

  • Proximity-dependent biotin identification (BioID)

  • Cross-linking mass spectrometry

  • Protein microarrays to identify binding partners

Given that Bcep18194_A4425 belongs to the UPF0060 family of uncharacterized membrane proteins, identifying its interacting partners and affected cellular processes upon depletion would provide valuable insights into its biological role .

What considerations should be made when designing experiments to study potential drug interactions with Bcep18194_A4425?

When investigating drug interactions with Bcep18194_A4425, researchers should address several key considerations:

• Binding Site Identification:

  • Computational docking simulations to predict binding pockets

  • Site-directed mutagenesis of predicted binding residues

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to identify regions protected upon drug binding

• Binding Kinetics Characterization:

  • Surface plasmon resonance (SPR) for real-time binding analysis

  • Isothermal titration calorimetry (ITC) for thermodynamic parameters

  • Fluorescence anisotropy for solution-based binding studies

• Functional Impact Assessment:

  • Transport assays if Bcep18194_A4425 functions as a transporter

  • Enzyme activity assays if it possesses enzymatic functions

  • Structural changes using circular dichroism spectroscopy

• Specificity Determination:

  • Counterscreening against related membrane proteins

  • Off-target binding evaluation using proteome-wide approaches

  • Selectivity index calculations comparing target vs. off-target effects

Experimental design should include appropriate controls, concentration ranges spanning at least two orders of magnitude around the expected IC50, and multiple technical and biological replicates to ensure statistical robustness .

What are the current knowledge gaps regarding Bcep18194_A4425 and how might future research address them?

Despite available information about the sequence and expression of Bcep18194_A4425, significant knowledge gaps remain:

• Functional Characterization: The precise biological function of Bcep18194_A4425 remains unknown, as indicated by its classification in the UPF0060 family of uncharacterized proteins.

• Structural Information: Detailed three-dimensional structural data is lacking, limiting structure-based functional predictions.

• Physiological Relevance: The role of Bcep18194_A4425 in Burkholderia lata physiology, pathogenicity, or environmental adaptation is undefined.

• Evolutionary Conservation: Comparative analysis across bacterial species could provide insights into functional importance.

Future research directions might include:

• Comprehensive structure determination using cryo-EM or X-ray crystallography

• Systematic mutagenesis to identify functionally important residues

• Interactome studies to place Bcep18194_A4425 in cellular pathways

• Phenotypic characterization of knockout mutants under various environmental conditions

By addressing these knowledge gaps, researchers can better understand this membrane protein's role and potential applications in biotechnology or drug development .